万邦德创新药研发获突破 股价涨停后小幅回调

Group 1 - The core viewpoint of the news is that Wanbangde (002082) experienced a significant stock price increase due to advancements in innovative drug development, particularly for Alzheimer's disease and ALS treatments [1] - The company's Alzheimer's drug, Shisujianjia controlled-release tablets, completed the enrollment of 100 subjects in a key Phase II/III clinical trial, and the ALS drug received FDA orphan drug designation [1] - Wanbangde's project has been included in the National Science and Technology Major Project, highlighting its technological strength [1] Group 2 - The stock price of Wanbangde increased by 17.00% over the past week, with a trading range fluctuation of 25.00% [2] - Following the stock price surge on February 10, it slightly declined to 18.58 yuan on February 11, with a minor decrease of 0.05% and a trading volume of 5.36 billion yuan [2] - The capital flow indicates a strong short-term interest, with a net inflow of 55.66 million yuan on February 10 and 0.91 million yuan on February 11 [2]